Form D · Biotechnology
Kv1.3 Therapeutics, Inc.
Seattle, WA · CIK 0001725094
Offering snapshot reported Jan 10, 2018 · SEC filing
- Reported sold
- $168K Offering amount: $5M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 5, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 10, 2018 | Initial | $168,182 | No comparison | 3 | SEC filing |
| Dec 13, 2017 | Initial | $16,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-302850
Source: Form D, filed Jan 10, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lucien Fouke | Director |
| Robert Hedequist | Director |
| Shawn Iadonato | Director |
| Gavin Jancke | Director |
| Craig Philips | Executive |
| Daniel Raymond | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
219 Terry Ave. N. Suite 300
Seattle, WA, 98092
Seattle, WA, 98092